Fresh analysis suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional lifestyle plans.
Research printed in a leading medical journal shows that while obese people often shed substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these medications need to be informed of the danger of quick rebound weight gain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to starting weight within about a year and a half.
Comparing Treatments
The study, which examined dozens of studies involving thousands of participants, compared the results of the injectable medications with older methods.
Researchers point out that individuals who shed pounds through dieting usually have a less rapid weight regain—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors suggest the way of the jabs explains the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 levels far above than normal could lead to the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, given the significant potential of weight regain, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the findings "underscore the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have stopped the medication report a powerful return of hunger.
"I experienced a trigger activating and you're instantly ravenous," recalled one woman.
The struggle is exacerbated if individuals have not developed permanent dietary or behavioural changes during therapy.
Growing Interest
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, experts caution that while the jabs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits relies on ongoing behavioural support.
